Terms: = Skin cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716
77 results:
1. The role of thymic stromal lymphopoietin in cutaneous disorders.
Jafari AJ; Rivera M; Hebert AA
Arch Dermatol Res; 2024 Apr; 316(5):123. PubMed ID: 38630260
[TBL] [Abstract] [Full Text] [Related]
2. Radix Tetrastigma Hemsleyani Flavone represses cutaneous squamous cell carcinoma via Janus kinase/signal transducer and activator of transcription 3 pathway inactivation.
Peng J; Luo X; Wang T; Yue C; Duan M; Wu C
Cytokine; 2024 Mar; 175():156480. PubMed ID: 38232644
[TBL] [Abstract] [Full Text] [Related]
3. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
Boldrini V; Vannucchi AM; Guglielmelli P
Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
[TBL] [Abstract] [Full Text] [Related]
4. Sensory neurons promote immune homeostasis in the lung.
Tamari M; Del Bel KL; Ver Heul AM; Zamidar L; Orimo K; Hoshi M; Trier AM; Yano H; Yang TL; Biggs CM; Motomura K; Shibuya R; Yu CD; Xie Z; Iriki H; Wang Z; Auyeung K; Damle G; Demircioglu D; Gregory JK; Hasson D; Dai J; Chang RB; Morita H; Matsumoto K; Jain S; Van Dyken S; Milner JD; Bogunovic D; Hu H; Artis D; Turvey SE; Kim BS
Cell; 2024 Jan; 187(1):44-61.e17. PubMed ID: 38134932
[TBL] [Abstract] [Full Text] [Related]
5. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P; Iannotti N; Cho DC; Kirkwood JM; Villaruz LC; Gibney GT; Hodi FS; Mettu NB; Jones M; Bowman J; Smith M; Lakshminarayanan M; O'Day S
Cancer Res Commun; 2023 Dec; 3(12):2572-2584. PubMed ID: 38115208
[TBL] [Abstract] [Full Text] [Related]
6. Successful treatment of jak1-associated inflammatory disease.
Fayand A; Hentgen V; Posseme C; Lacout C; Picard C; Moguelet P; Cescato M; Sbeih N; Moreau TRJ; Zhu YYJ; Charuel JL; Corneau A; Deibener-Kaminsky J; Dupuy S; Fusaro M; Hoareau B; Hovnanian A; Langlois V; Le Corre L; Maciel TT; Miskinyte S; Miyara M; Moulinet T; Perret M; Schuhmacher MH; Rignault-Bricard R; Viel S; Vinit A; Soria A; Duffy D; Launay JM; Callebert J; Herbeuval JP; Rodero MP; Georgin-Lavialle S
J Allergy Clin Immunol; 2023 Oct; 152(4):972-983. PubMed ID: 37343845
[TBL] [Abstract] [Full Text] [Related]
7. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Landis MN; Smith SR; Berstein G; Fetterly G; Ghosh P; Feng G; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Beebe JS; Tarabar S
Br J Dermatol; 2023 Jul; 189(1):33-41. PubMed ID: 36972293
[TBL] [Abstract] [Full Text] [Related]
9. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
Jaeger A; Gambheer SMM; Sun X; Chernyakov D; Skorobohatko O; Mack T; Kissel S; Pfeifer D; Zeiser R; Fisch P; Andrieux G; Bräuer-Hartmann D; Bauer M; Schulze S; Follo M; Boerries M; von Bubnoff N; Miething C; Hidalgo JV; Klein C; Weber T; Wickenhauser C; Binder M; Dierks C
Blood; 2023 Jun; 141(23):2824-2840. PubMed ID: 36696631
[TBL] [Abstract] [Full Text] [Related]
10. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract] [Full Text] [Related]
11. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma.
Gluud M; Pallesen EMH; Buus TB; Gjerdrum LMR; Lindahl LM; Kamstrup MR; Bzorek M; Danielsen M; Bech R; Monteiro MN; Blümel E; Willerslev-Olsen A; Lykkebo-Valløe A; Vadivel CK; Krejsgaard T; Bonefeld CM; Geisler C; Becker JC; Koralov SB; Iversen L; Litman T; Woetmann A; Ødum N
Blood; 2023 Jan; 141(2):180-193. PubMed ID: 36122387
[TBL] [Abstract] [Full Text] [Related]
12. Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling.
Shen H; Huang F; Zhang X; Ojo OA; Li Y; Trummell HQ; Anderson JC; Fiveash J; Bredel M; Yang ES; Willey CD; Chong Z; Bonner JA; Shi LZ
Nat Commun; 2022 Aug; 13(1):5013. PubMed ID: 36008408
[TBL] [Abstract] [Full Text] [Related]
13. A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogeneic stem cell transplant.
Davies A; Salisbury J; Mehra V; Papa S; Basu T
Clin Exp Dermatol; 2022 Nov; 47(11):2059-2064. PubMed ID: 36004622
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Landis MN; Arya M; Smith S; Draelos Z; Usdan L; Tarabar S; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Sikirica V; Xenakis J; Beebe JS
Br J Dermatol; 2022 Dec; 187(6):878-887. PubMed ID: 35986699
[TBL] [Abstract] [Full Text] [Related]
15. Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M; Presti M; Sztupinszki Z; Jensen AWP; Draghi A; Chamberlain CA; Schina A; Yde CW; Wojcik J; Szallasi Z; Crowther MD; Svane IM; Donia M
Cancer Immunol Res; 2022 Oct; 10(10):1254-1262. PubMed ID: 35969233
[TBL] [Abstract] [Full Text] [Related]
16. Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance.
Breccia M; Palandri F; Guglielmelli P; Palumbo GA; Malato A; Mendicino F; Ricco A; Sant'Antonio E; Tiribelli M; Iurlo A
Curr Oncol; 2022 Jul; 29(7):4970-4980. PubMed ID: 35877255
[TBL] [Abstract] [Full Text] [Related]
17. Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis.
Yi G; Huang Z; Huang Z; Wang Y; Deng W; Zheng S; Li T
Front Immunol; 2022; 13():914265. PubMed ID: 35874753
[TBL] [Abstract] [Full Text] [Related]
18. The Natural Janus Kinase Inhibitor Agerarin Downregulates Interleukin-4-Induced
Lee JY; Jung E; Yeo H; Ahn SS; Lim Y; Lee YH
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807451
[TBL] [Abstract] [Full Text] [Related]
19. Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells.
Margolis N; Moalem H; Meirson T; Galore-Haskel G; Markovits E; Baruch EN; Vizel B; Yeffet A; Kanterman-Rifman J; Debby A; Besser MJ; Schachter J; Markel G
Cancer Immunol Res; 2022 Sep; 10(9):1127-1140. PubMed ID: 35731225
[TBL] [Abstract] [Full Text] [Related]
20. Be Easy and Chill: Melanoma Cells Tell Lymph Node Fibroblasts to Relax.
Lund AW
Cancer Res; 2022 May; 82(9):1692-1694. PubMed ID: 35502545
[TBL] [Abstract] [Full Text] [Related]
[Next]
